Cargando…
Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study
BACKGROUND: We conducted an investigator-initiated, phase I trial of vincristine sulfate liposomal injection (VSLI) in combination with bendamustine and rituximab (BR) for indolent B-cell (BCL) or mantle cell lymphoma. METHODS: Participants received 6 cycles of standard BR with VSLI at patient-speci...
Autores principales: | Ollila, Thomas, Butera, James, Egan, Pamela, Reagan, John, Thomas, Anthony, Yakirevich, Inna, MacKinnon, Kelsey, Margolis, Jeannine, McMahon, Jessica, Rosati, Valerie, Olszewski, Adam J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255974/ https://www.ncbi.nlm.nih.gov/pubmed/35641232 http://dx.doi.org/10.1093/oncolo/oyab079 |
Ejemplares similares
-
Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study
por: Pelcovits, Ari, et al.
Publicado: (2023) -
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019) -
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022) -
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023) -
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)